Board of Directors
Board of Directors
Alvin E. McQuinn | Chairman and CEO, QuinStar Investment Partners
Mr. McQuinn is Chairman and CEO of QuinStar Investment Partners. Previously, he founded Ag-Chem Equipment Company in 1963 and served as its Board Chairman and CEO. Mr. McQuinn grew Ag-Chem into a NASDAQ-listed creator, manufacturer, and marketer of equipment and data management systems for satellite-guided application of fertilizers and farm chemicals. The company revolutionized crop farming and grew rapidly to more than 1,700 employees generating more than $300 million in annual sales. In 2001, Ag-Chem was purchased by AGCO Corporation, which provides high-tech solutions to farmers worldwide. Mr. McQuinn received the Siteliner Lifetime Achievement Award in 2001 for his efforts in the development of site-specific farming in precision agriculture, and he is the named inventor on six patents in that area. His other recognitions include the John F. Cade Award for Entrepreneur of the Year, the Ernst and Young Entrepreneur Award in the Master Category for Minnesota and the Dakotas, the University of Minnesota’s Lifetime Achievement Award for Precision Agriculture, and induction into the Minnesota Business Hall of Fame. He is a member of the Board of Trustees for the University of St. Thomas in St. Paul, Minnesota and serves on the Minneapolis-St. Paul Leadership Council of Mayo Clinic Rochester. Mr. McQuinn graduated from the University of Missouri in 1954 with a BSc in Agricultural Economics. While attending the University, he earned an ROTC commission as an officer in the U.S. Army. He served four years, attended flight school, and completed service with 1,500 hours of pilot in command. During his civilian business career, he used airplanes with great advantage to build his business.
Ahryon Cho, PhD | Investment Division / General Manager, Mirae Asset
Ahryon Cho is a general manager at Mirae Asset Venture Investment (MAVI) based in Korea, and MAVI is the venture capital arm of Mirae Asset group that is one of the renowned, largest financial service group in Asia. Since joining Mirae Asset group in 2016, she has completed multiple equity investments in companies developing innovative therapeutics and diagnostics, and been serving the board of directors of her portfolio companies.
Prior to joining Mirae Asset group, she was a research assistant professor at Yonsei University School of Medicine from 2014 to 2016. She received her Ph.D. in Molecular Biology and Neuroscience at Princeton University, NJ, USA, and completed her post-doctoral training in Pathology at Stanford University School of Medicine, CA, USA. One of her post-doctoral researches resulted in the foundation of a biotech company based in CA, USA that is currently in pre-clinical stage.
Daniel Geffken | Managing Partner, Danforth Advisors
Daniel Geffken is a Founder and Managing Director of Danforth Advisors. Daniel brings more than 22 years of experience in the life science industry to his work with Danforth Advisors clients, ranging from early start-ups to publicly traded companies with $1 billion+ market capitalizations. Previously, he has served as COO or CFO of four publicly traded and four privately held companies, in addition to his consulting clients, and was interim CEO of a medical device company. In these roles, he has had management responsibility for finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property, and manufacturing functions. Daniel has assisted in raising more than $1 billion in equity and debt securities. He serves on the Board of Directors for Alcobra, a biopharmaceutical company that completed an initial public offering in May 2013. He has a BS in Economics from The Wharton School, University of Pennsylvania and an MBA from Harvard Business School.
Andrew Khoo | Chief Executive Officer & Co-Founder, Tessa Therapeutics
Andrew Khoo is the CEO and Co-founder of Tessa therapeutics, an international biotechnology company specialized in virus-associated cancer immunotherapy. Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors such as nose, cervical, liver, lung, and stomach cancer. Under Mr. Khoo’s leadership, Tessa has grown to become a 100+ employee company, with operations across 5 countries, and is also currently running the world’s largest phase 3 adoptive T cell therapy trial for any cancer indication.
An active investor in healthcare and technology focused start-ups, Mr. Khoo is also a Director of other leading biotechnology companies such as Euchloe Bio and Enleofen Bio, that specialize in the development and commercialization of antibodies to treat cancer and fibrotic diseases, respectively.
Prior to his involvement with Tessa, Mr. Khoo worked in various roles at global investment banks including JP Morgan and Citigroup. He began his career at the Singapore Economic Development Board after graduating from Stanford University on a full government scholarship.
Stephen J. Russell, MD, PhD | Co-Founder, Director, and President & CEO, Vyriad
Stephen Russell is President and Chief Executive Officer of Vyriad. Previously, Dr. Russell was a Co-Founder and President of Magnis Therapeutics, which Vyriad acquired in 2015, and he is a Co-Founder of Imanis Life Sciences. Dr. Russell is a leading expert in the development and translation of novel viral-based cancer therapeutics and a clinician scientist with more than 30 years of experience in the management of hematological malignancies. Since 2006, he has served as the Richard O. Jacobson Professor of Molecular Medicine at the Mayo Clinic, where he previously held various leadership positions, including Founding Chair of the Department of Molecular Medicine (2005-2007), Dean of Discovery and Experimental Research (2006-2013), Associate Director for Translational Research of the Cancer Center (2012-2015), and Deputy Director for Translation in the Center of Regenerative Medicine (2013-2015). From 1998 to 2009, Dr. Russell was the founding Director of Mayo Clinic’s Molecular Medicine Program, which includes more than 100 scientists and has become a world-renowned program in oncolytic virotherapy and associated infrastructure. Prior to his tenure with Mayo Clinic, Dr. Russell was a clinician scientist at the Medical Research Council Laboratory for Molecular Biology in Cambridge, United Kingdom, where he also founded Cambridge Genetics, a biotechnology/drug discovery company that was subsequently acquired by Galapagos NV. Dr. Russell received his MD from University of Edinburgh and his PhD in Retrovirology from University College London, and he trained at University College Hospital and the Royal Marsden Hospital in the United Kingdom.
Glen N. Barber, PhD | Co-Founder and Director, Vyriad
Glen Barber is Professor (2008-present) and Chairman (2011-present) of the Department of Cell Biology, Associate Director for Basic Research, and Eugenia Dodson Chair in Cancer Research of the Sylvester Comprehensive Cancer Center (2006-present) at the University of Miami Miller School of Medicine, Florida. He is an internationally recognized scientist in the field of innate immune defense and antiviral strategies, with more than 150 scientific publications, many in high-profile journals such as Nature, Science, and Cell. Since joining the University of Miami in 1999, Dr. Barber has been developing novel vesicular stomatitis virus (VSV) therapeutics and led cutting-edge research in understanding the mechanisms of innate immunity to viral infection and malignant disease, including the recent discovery of STING and the elucidation of its role in innate immunity. He is also the CEO and President of STINGINN, a company he founded based on his STING technology. Dr. Barber received his PhD in Molecular Virology at London University, England.